Total Payments
$83,024
2024 Payments
$12,242
Companies
10
Transactions
89
Medicare Patients
1,258
Medicare Billing
$164,673
Payment Breakdown by Category
Consulting$70,370 (84.8%)
Travel$7,071 (8.5%)
Research$3,221 (3.9%)
Food & Beverage$2,362 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $70,370 | 18 | 84.8% |
| Travel and Lodging | $7,071 | 27 | 8.5% |
| Unspecified | $3,221 | 15 | 3.9% |
| Food and Beverage | $2,362 | 29 | 2.8% |
Payments by Type
General
$79,803
74 transactions
Research
$3,221
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $27,844 | 15 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $14,573 | 14 | $0 (2024) |
| Merck Sharp & Dohme LLC | $11,458 | 10 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $7,777 | 10 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,529 | 20 | $0 (2024) |
| Incyte Corporation | $7,227 | 10 | $0 (2023) |
| PFIZER INC. | $5,660 | 7 | $0 (2018) |
| Almirall LLC | $800.00 | 1 | $0 (2024) |
| Vectura Limited | $129.00 | 1 | $0 (2019) |
| Kaleo, Inc. | $26.58 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $12,242 | 19 | E.R. Squibb & Sons, L.L.C. ($6,451) |
| 2023 | $21,524 | 25 | E.R. Squibb & Sons, L.L.C. ($8,121) |
| 2022 | $4,426 | 5 | GENZYME CORPORATION ($2,300) |
| 2021 | $7,418 | 3 | GENZYME CORPORATION ($7,418) |
| 2020 | $4,496 | 1 | GENZYME CORPORATION ($4,496) |
| 2019 | $20,592 | 13 | GENZYME CORPORATION ($13,630) |
| 2018 | $12,300 | 22 | Merck Sharp & Dohme Corporation ($5,818) |
| 2017 | $26.58 | 1 | Kaleo, Inc. ($26.58) |
All Payment Transactions
89 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,320.00 | General |
| 10/24/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $126.98 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $95.37 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/14/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $123.20 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/03/2024 | Almirall LLC | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 09/16/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $24.24 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $102.56 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/30/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $24.24 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $104.92 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/12/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $32.57 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 07/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,010.00 | General |
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $48.48 | Research |
| Study: LIBTAYO CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: ONCOLOGY | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $859.54 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $141.45 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $135.85 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: ONCOLOGY | ||||||
| 01/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $60.64 | General |
| 01/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.64 | General |
| 12/19/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $5,490.00 | General |
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $685.00 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $435.80 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $179.67 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $3,221 | 15 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 254 | 372 | $183,623 | $36,256 |
| 2022 | 12 | 334 | 559 | $219,204 | $44,425 |
| 2021 | 11 | 371 | 627 | $234,360 | $53,871 |
| 2020 | 11 | 299 | 464 | $146,831 | $30,120 |
Total Patients
1,258
Total Services
2,022
Medicare Billing
$164,673
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 73 | 126 | $79,918 | $15,218 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 70 | 92 | $37,166 | $7,440 | 20.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 16 | 49 | $21,923 | $4,937 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $22,428 | $4,295 | 19.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $8,855 | $1,615 | 18.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 15 | 18 | $7,266 | $1,480 | 20.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 41 | 48 | $6,067 | $1,271 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 65 | 120 | $73,374 | $14,457 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 117 | $46,659 | $9,458 | 20.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 65 | $26,455 | $5,690 | 21.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 24 | 24 | $18,300 | $3,766 | 20.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $12,624 | $2,730 | 21.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 40 | $11,320 | $2,406 | 21.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 15 | 15 | $6,345 | $1,370 | 21.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 19 | 27 | $6,120 | $1,318 | 21.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 12 | 15 | $5,985 | $1,188 | 19.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 20 | $5,378 | $1,040 | 19.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 29 | 34 | $4,334 | $883.44 | 20.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 15 | 66 | $2,310 | $119.02 | 5.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 80 | 173 | $90,531 | $21,633 | 23.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 90 | 139 | $46,830 | $11,187 | 23.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 23 | 72 | $30,168 | $6,436 | 21.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 34 | 34 | $23,820 | $5,491 | 23.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 16 | $13,056 | $2,773 | 21.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 40 | 56 | $7,469 | $1,570 | 21.0% |
About David Miller, M.D., PH.D
David Miller, M.D., PH.D is a Dermatology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2010. The National Provider Identifier (NPI) number assigned to this provider is 1356662373.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Miller, M.D., PH.D has received a total of $83,024 in payments from pharmaceutical and medical device companies, with $12,242 received in 2024. These payments were reported across 89 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($70,370).
As a Medicare-enrolled provider, Miller has provided services to 1,258 Medicare beneficiaries, totaling 2,022 services with total Medicare billing of $164,673. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Boston, MA
- Active Since 06/14/2010
- Last Updated 07/31/2015
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1356662373
Products in Payments
- LIBTAYO (Biological) $28,576
- LIBTAYO (Drug) $10,265
- NO PRODUCT DISCUSSED (Drug) $3,365
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $820.71
- EYLEA HD (Biological) $123.20
- Auvi-Q (Drug) $26.58
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Boston
Dr. Alexandra Kimball, Md Mph, MD MPH
Dermatology — Payments: $649,180
Dermatology $649,180
Dr. Maryanne Senna, M.d, M.D
Dermatology — Payments: $393,215
Dermatology $393,215
Brian Hibler
Dermatology — Payments: $324,366
Dermatology $324,366
Dr. Emmy Graber, M.d, M.D
Dermatology — Payments: $282,461
Dermatology $282,461
Dr. Mathew Avram, Md, MD
Dermatology — Payments: $228,216
Dermatology $228,216
Ruth Ann Vleugels, Md, MD
Dermatology — Payments: $194,613
Dermatology $194,613